APTV Form 144 Filing Reports 6,539 Shares for Sale via Fidelity ($523,120)
Rhea-AI Filing Summary
Aptiv PLC (APTV) filed a Form 144 reporting a proposed sale of 6,539 common shares through Fidelity Brokerage Services (NYSE) with an aggregate market value of $523,120 and approximately 217,759,811 shares outstanding. The shares were acquired as restricted stock vesting from the issuer: 5,437 shares vested on 02/28/2023 and 1,102 shares vested on 02/28/2024, both recorded as compensation. The filing shows no securities sold by the reporting person in the past three months and lists an approximate sale date of 08/26/2025. The filer represents they are unaware of undisclosed material adverse information.
Positive
- Disclosure of acquisition details: Vesting dates and share counts (5,437 and 1,102) are explicitly provided.
- No prior sales in past 3 months, reducing aggregation complexity under Rule 144.
- Broker identified (Fidelity Brokerage Services LLC), improving transaction transparency.
Negative
- Insider sale planned of 6,539 shares (aggregate value $523,120) which increases available float.
- Potential perception risk: Insider selling of vested compensation may draw investor attention despite small size.
Insights
TL;DR: Routine insider sale notice for vested restricted stock; modest size relative to outstanding shares, likely non-material to valuation.
The Form 144 shows a proposed sale of 6,539 vested shares acquired as compensation across two vesting dates. At an aggregate market value of $523,120, this sale equals roughly 0.003% of the reported outstanding shares (217.76 million), indicating limited dilution or market impact. Absence of any sales in the prior three months suggests this is a scheduled disposition of vested compensation rather than an accelerated liquidation.
TL;DR: Filing discloses standard compliance with Rule 144 and a statement about material non-public information; procedural transparency is appropriate.
The notice identifies the broker and confirms the shares arose from restricted stock vesting, with compensation listed as the payment nature. The filer attests to no undisclosed material adverse information and provides a planned sale date, which aligns with regulatory expectations for transparency around insider dispositions. No prior 3-month sales are reported, simplifying aggregation rules under Rule 144.